Expert Interview
Discussing Amgen's Phase 3 trials for Uplizna (Inebilizumab-CDON) in treating myasthenia gravis in acetylcholine receptor-antibody positive patients
Ticker(s): AMGN- Assistant Professor of Neurology at Cleveland Clinic
- Manages 10-15 patients with Myasthenia Gravis
- Serves as Director of Inpatient General Neurology and specializes in managing central nervous system inflammatory disorders
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
